Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Ovarian, fallopian tube, or primary peritoneal cancer, collectively referred to as ovarian cancer, remains the deadliest type of gynaecological cancer. The most common and aggressive form is called high-grade serous ovarian cancer. The main purpose of this study is to understand whether an experimental study vaccine, CryptiVax-1001, is safe when administered to patients with high-grade serous ovarian cancer (HGSOC). The study vaccine is a cancer vaccine, which aims to delay or possibly prevent the cancer from coming back. However, as this is the first study of the vaccine in patients, the primary purpose of this study is to assess the safety of the study vaccine. Following surgery and platinum-based chemotherapy participants may enter the trial and receive CryptiVax-1001 as an explorative maintenance therapy. The main purposes of this study are therefore to: * assess how well the study vaccine is tolerated and identify any side effects. * analyse the study vaccine's capacity to activate your immune system The study will test escalating dose levels of CryptiVax-1001 based on the safety evaluations to estimate appropriate future dose levels for CryptiVax-1001.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobiety powyżej 18 roku życia, które rozumieją i zgadzają się na udział w badaniu.
- •Leczony zaawansowany rak jajnika, jajowodu lub otrzewnej, który jest agresywnym typem raka.
- •Pacjentki, u których choroba została zdiagnozowana na etapie III lub IV.
- •Po zakończeniu operacji i chemioterapii, która obejmowała leki z grupy platyny.
- •Pacjentki, u których po chemioterapii nie stwierdzono postępu choroby.
- •Okres od zakończenia chemioterapii do rozpoczęcia badania wynosi od 4 do 12 tygodni.
- •Ogólny stan zdrowia pozwalający na udział w badaniu (ocena lekarza).
- •Prawidłowe wyniki badań krwi i narządów.
✗ Disqualifies
- •Inne typy nowotworów jajnika, które nie są agresywne.
- •Aktywny, niekontrolowany płyn w jamie brzusznej lub opłucnej.
- •Inne choroby nowotworowe w ciągu ostatnich 3 lat (z wyjątkiem tych o bardzo niskim ryzyku nawrotu).
- •Aktywne choroby autoimmunologiczne wymagające leczenia.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 14, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (10)
Cambridge University Hospitals NHS Foundation Trust - Addenbrookes Hospital
Cambridge, United Kingdom
The University of Edinburgh - Western General Hospital - Edinburgh Cancer Research Centre
Edinburgh, United Kingdom
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
St. James's University Hospital
Leeds, United Kingdom
University Hospitals of Leicester NHS Trust -Leicester Royal Infirmary
Leicester, United Kingdom
University College London Hospitals NHS Foundation Trust - Cancer Clinical Trials Unit
London, United Kingdom
Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital
London, United Kingdom
Royal Marsden NHS Foundation Trust - Royal Marsden Hospital
London, United Kingdom
Lancashire Teaching Hospitals NHS Foundation Trust - Royal Preston Hospital
Preston, United Kingdom
Royal Marsden NHS Foundation Trust - Institute of Cancer Research
Sutton, United Kingdom
Trial contact
Head of Development Operations
Head of Oncology Development
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.